Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)

Ayalew Tefferi, Kebede H. Begna, Kristen B. McCullough

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)1394-1397
Number of pages4
JournalAmerican journal of hematology
Issue number11
StatePublished - Nov 2022

ASJC Scopus subject areas

  • Hematology

Cite this